Skip to main content

Publications

Peer Reviewed Articles

(partial listing, 2017 - present)

  • Maksimova V, Smith S, Seth J., Phelps C, Niewiesk S, Satou Y, Green PL, Panfil AR. HTLV-1 intragenic viral enhancer influences immortalization phenotype in vitro, but is dispensable for persistence and disease development in animal models. Front in Immunol. DOI: 10.3389/fimmu.2022.954077.
  • Moore RM, Green PL, Fingland RB, Hare T. Impactful research improving animal health through a one health approach. AM J Vet Res 2022. Vol 83:Issue 8. https://doi.org/10.2460/ajvr.22.06.0103.
  • Daenthanasanmak A, Bamford RN, Yoshioka M, Yang S-M, Homan P, Karim B, Bryant BR, Petrus MN, Thomas CJ, Green PL, Miljkovic MD, Conlon KC, Waldmann TA. Triple combination of BET plus PI3K and NF-κB inhibitors exhibit synergistic activity in adult T cell leukemia/lymphoma. Blood Advances 2022 Jan 14; doi: 10.1182/bloodadvances. 2021005948. Oneline ahead of print. PMID: 35030628.
  • Ishio T, Kumar S, Shimono J, Daenthanasanmak A, Dubois S, Lin Y, Bryant BR, Petrus MN, Bachy E, Huang DW, Yang Y, Green PL, Hasegawa H, Maeda M, Goto H, Endo T, Yokota T, Hatanaka KC, Hatanaka Y, Tanaka S, Matsuno Y, Yang Y, Hashino S, Teshima T, Waldmann TA, Staudt LM, Nakagawa M. Genome-wide CRISPR screen identifies CDK6 as a therapeutic target in Adult T-cell leukemia/lymphoma. Blood. 2021 Nov 24:blood.2021012734. doi: 10.1182/blood.2021012734. Online ahead of print. PMID: 34818414.
  • Cheng X, Joseph A, Castro V, Chen-Liaw A, Skidmore Z, Ueno T, Fujisawa JI, Rauch DA, Challen GA, Martinez MP, Green PL, Griffith M, Payton JE, Edwards JR, Ratner L. Epigenomic regulation of human T cell leukemia virus by chromatin-insulator CTCF. PLoS Pathog. 2021 May 21;17(5):31009577. doi:10.1371/journal.ppat.1009577. eCollection 2021 May. PMID: 34019588 PMCID: PMC8174705
  • Panfil AR, Green PL, Yoder KE. CRISPR genome editing applied to the pathogenic retrovirus HTLV-1. Front Cell Infect Microb. 2020 Dec23;10:580371.doi:10.3389/fcimb.2020.580371. PMCID:PMC7785941
  • Panfil AR, Green PL. HTLV-1 and HTLV-2. In: Encyclopedia of Virology Fourth Edition. Bramford D and Zuckerman M, editors. . Volume 2, 2021, Pages 528-539. Elsevier. https://doi.org/10.1016/B978-0-12-809633-8.21225-9
  • Martinez MP, Cheng X, Ancy JJ, Al-Saleem J, Panfil A, Palettas M, Dirksen WP, Ratner L, Green, PL. HTLV-1 CTCF-Binding Site is Dispensable for In Vitro Immortalization and Persistent Infection In Vivo. Retrovirology, 2019 Dec 21;16(1):44. doi: 10.1186/s12977-019-0507-9. PMCID: PMC6925871.
  • Xiang J, Huey D, Rauch DA, Panfil A, Cheng X, Harding JC, Su X, Fontana F, Xu Y, Esser A, Wong W-H, Jia J, SundaramoorthiH, Wu K, Rosol TJ, Veis D, Green PL, Ratner L, Niewiesk S, Weilbaecher KN. HTLV-1 Viral Oncogene HBZ Drives Bone Destruction in Adult T Cell Leukemia. JCI Insight. 2019 Oct 3;4(19). pii: 128713. doi: 10.1172/jci.insight.128713. PMCID: PMC6795409.
  • Kohart NA, Elshafae SM, Supsahvad W, Alasonyalilar-Demirer A, Panfil AR, Xiang J, Dirksen WP, Veis DJ, Green PL, Weilbaecher KN, Rosol TJ. Mouse Model Recapitulates the Phenotypic Heterogeneity of Human Adult T-cell Leukemia/Lymphoma in Bone. J Bone Oncology 2019 Aug 20;19:100257. doi: 10.1016/j.jbo.2019.100257. eCollection 2019 Dec. PMCID: PMC6911918.
  • Martinez MP, Al-Saleem JJ, Green PL: Comparative Virology of HTLV-1 and HTLV-2. Retrovirology, 2019 Aug 7;16(1):21. doi: 10.1186/s12977-019-0483-0. PMCID: PMC6686503.
  • Al-Saleem JJ, Kvaratskhelia M, Ratner L, Green PL: Identification and Characterization of a novel Tax-1 interacting protein, SNX27, and its role in HTLV-1 pathobiology. PLoS One 2019 Mar 21;14(3):30214059. doi: 10.1371/journal.pone.0214059. eCollection 2019. PMCID: PMC6428263.
  • Panfil AR, London JA, Green PL, Yoder KE. CRISPR/Cas9 genome editing to disable the latent HIV-1 provirus. Frontiers in Microbiol, 2018, December 14. doi: 10.3389/fmicb.2018.03107.
  • Kodigepalli KM, Li M, Bonifati S, Panfil A, Green PL, Liu S-L, Wu L. SAMHD1 inhibits epithelial cell transformation in vitro and affects leukemia development in xenograft mice. Cell Cycle Doi: 10.1080/15384101.2018.1550955 PMCID: PMC6300106.
  • Nakagawa M, Shaffer III AL, Ceribelli M, Zhang M, Wright G, Huang DW, Xiao W, Powell J, Petrus MN, Yang Y, Phelan JD, Kohlhammer H, Dubois SP, Yoo HM, Bachy E, Webster DE, Yang Y, Xu W, Yu X, Zhao H, Bryant BR, Shimono J, Ishio T, Maeda M, Green PL, Waldmann TA, Staudt LM: Targeting the HTLV-1-regulated BATF3/IRF4 transcriptional network in adult T-cell leukemia/lymphoma. Cancer Cell August 13, 2018 34, 286-297. PMID: 30057145.
  • Panfil AR, Howard CM, Shkriabai N, Kvaratskhelia M, Green PL: Stability of the HTLV-1 antisense derived protein, HBZ, is regulated by the E3 ubiquitin ligase, UBR5. Front Microbiol. 2018 Jan 30;9:80. doi: 10.3389/fmicb.2018.00080. eCollection 2018. PMCID: PMC5797633.
  • Huey D, Bolon B, La Perle KMD, Kannian P, Jacobson S, Ratner L, Green PL, Niewiesk S. Wild type and recombinant human T cell leukemia viruses induce lymphoproliferative disease in humanized NSG mice. Comp Med. 2018 Feb 1;68(1):4-14. PMCID: PMC5824134.
  • Esser A, Rauch D, Xiang J, Harding J, Kohart N, Ross M, Su X, Wu K, Huey D, Xu Y, Green PL, Rosol TJ, Niewiesk S, Ratner L, Weilbaecher K.HTLV-1 Viral Oncogene HBZ induces Osteolytic Bone Disease in Transgenic Mice. Oncotarget. 2017 Aug 27;8(41):69250-69263. doi: 10.18632/oncotarget 02565. PMCID: PMC5642476.
  • Kenny A, Dowdle JA, Bozzacco L, McMichael TM, St. Gelais C, Panfil AR, Sun Y, Anderson MZ, Green PL, López CV, Rosenberg BR, Wu L, Yount JS: Human Genetic Determinants of Viral Diseases. Annual Reviews of Genetics, 2017 Nov 27;51:241-263. doi: 10.1146/annurev-genet-120116-023425. Epub 2017 Aug PMID: 28853921.
  • Al-Saleem J, Kvaratskhelia M, Green PL: Methods for identifying and examining HTLV-1 HBZ post-translational modifications. Methods Mol Biol. 2017;1582:111-126. doi: 10.1007/978-1-4939-6872-5_9. PMID: 28357666.
  • Webb LM, Amici SA, Jablonski K, Savardekar H, Panfil AR, Li L, Zhou W, Peine K, Karkhanis V, Bachelder E, Ainslie K, Green PL, Li C, Baiocchi RA, Guerau-de-Arellano M: Protein arginine methyltransferase 5 (PRMT5) selective inhibitors suppress inflammatory T cell responses and experimental autoimmune encephalomyelitis. J Immunol. 2017 Jan 13. pii: 1601702. doi: 10.4049/jimmunol.1601702. [Epub ahead of print] PMCID: PMC5292587.

Departments & Offices

Education

Alumni